Cardiac tolerability of paclitaxel-anthracyclin associations in breast cancer management;Tolérance cardiaque des associations paclitaxel-anthracyclines dans le cadre de la prise en charge du cancer du sein

Bulletin du Cancer

Volumn 90, Issue 3, 2003, Pages 219-226

  Ferrero, Jean Marc ^a   Magné, Nicolas ^a,b   Foa, Cyril ^a   Largillier, Rémy ^a   Namer, Moïse ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Cardiotoxicity; Doxorubicin; Paclitaxel

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; RAZOXANE;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MIXTURE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARRHYTHMIA; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DOXORUBICIN; FEMALE; HEART; HEART DISEASES; HUMANS; PACLITAXEL;

EID: 0037882268     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Burke MJ, Siegel BS, Davidow B. Consequence of yew needle ingestion. N Y State J Med 1979; 79: 1576-77.
2. Gueritre-Vogelein F, Guenard D, Mangatal L, et al. Structure of a synthetic taxol precursor: N-tert-buroxy-carbonyl-10-desacetyl-N debenzoytaxol. Acta Cryst 1990; 46: 781-84.
3. Arbuck S, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst 1993; 15: 117-30.
4. Danesi R, Conte PF, Del Tacca M. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. Clin Pharmacokin 1999; 37: 195-11.
5. Platel D, Pouma P, Bonoron-Adele S, Robert J. Preclinical evaluation of the cardiotoxicity of taxane-anthtacycline combinations using the model of isolated perfused rat heart. Toxicol Appl Pharmacol 2000; 163: 135-40.
6. Minotti G, Saponiero A, Licata S, Menna P, Calafiore AM, Teodori G, et al. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 2001; 7: 1511-5.
7. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-99.
8. Gehl J, Boesgaard M, Paaske T, et al. Combined doxorubkin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Annals Oncol 1996; 7: 687-93.
9. Schwartsmann G, Menke Ch, Caleffi M, et al. A phase II study of doxorubicin, paclitaxel plus G-CSF for metastatic breast cancer. Oncology 1997; 11: 24-9.
10. Amadori D, Milandri C, Tienghi A, et al. Phase I/II study: doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer. Oncology 1997; 11: 30-3.
11. Dombernowsky P, Boesgaard M, Andersen E, et al. Doxorubicin plus paclitaxel in advanced breast cancer. Semin Oncol 1997; 24: 15-8.
12. Martin M, Lluch A, Ojeda B, et al. Paclitaxel plus doxorubicin in metastatic breast cancer preliminary analysis cardiotoxicity. Semin Oncol 1997; 24: 17-26.
13. Sparano JA, Hu P, Rao RM, et al. Phase II trial of doxorubicin and paclitaxel plus G-CSF in metastatic breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1999; 17: 3828-34.
14. Gianni L, Bigano L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906-15.
15. Hortobagyi G, Willey J, Rahman Z, et al. Prospective assessment of cardiac toxicity during a randomised phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 1997; 24: 65-8.
16. Jovtis S, Mickiewicz E, Di Notto M, et al. No clinical cardiotoxicity associated with paclitaxel + doxorubicin as first-line treatment for metastatic breast cancer. Proc Am Soc Clin Oncol 1997; 16: 844.
17. Gianni L, Dombernowsky P, Sledge G, Martin M, Amadori D, Arbuck SG, et al. Cardiac function following combination therapy with paclitaxel and doxotubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 2001; 12: 1067-73.
18. Moreira A, Lobato R, Morais J, et al. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemother Pharmacol 2001; 48: 333-7.
19. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Knmpotic Z, et al. for the Central & Eastern Europe and Israel Paclitaxel Breast cancer Study Group. Doxorubicin and paclitaxel versus fluotouracil, doxotubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III multicenter trial. J Clin Oncol 2001; 19: 1707-15.
20. Conte PF, Baldini E, Gennari A, et al. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 1997; 15: 2510-7.
21. Esposito M, Venturini M, Vannozzi MO, et al. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncol 1999; 17: 1132-40.
22. Gennari A, Salvadori B, Donati S et al. Cardiotoxicity of epirubicinpaclitaxel-containing regimen: role of cardiac risk factors. J Clin Oncol 1999; 17: 3596-602.
23. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979; 300: 278-83.
24. McKillop JH, Britow MR, Goris ML, et al. Sensitivity and specificity of radionuclide ejection fraction in doxorubicin cardiotoxicity. Am Heart J 1983; 106: 1048-56.
25. Carmichael J, Jones A, Hutchinson T. A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. Semin Oncol 1997; 5: 44-7.
26. Luck HJ, Thomssen C, du Bois A, et al. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Semin Oncol 1997; 5: 35-9.
27. Conte PF, Gennari A, Tanganelli L, et al. Incidence of cardiotoxicity in patients treated with epirubicin/paclitaxel containing regimens. 9th International Congress on Anti-Cancer Treatment, Paris, Feb 2-5, 1999.
28. Ries F, Duhem C, Kleiber K, Dicato M. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer. Semin Oncol 1997; 24: 17-48.
29. Luck HJ, Thomssen C, Untch M, et al. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC): epitubicin/paclitaxel (ET) versus epitubicin/cyclophosphamide (EC). A study of the Ago Breast Cancer Group. Proc Am Soc Clin Oncol 2000; 19 (abstr. 280).
30. Hudis C, Riccio L, Seldman A, et al. Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. Cancer Invest 1998; 16: 67-71.
31. Sledge GW, Neuberg D, Ingle J, et al. Phase III trial of doxorubicin versus paclitaxel versus doxorubicin plus paclitaxel as first-line therapy for metastatic breast cancer: an intergroup trial. Proc Am Soc Clin Oncol 1997; 16: 1a (abstr. 2).
32. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: a prospective randomised evaluation. Cancer 1990; 65: 870-3.
33. Casper ES, Gaynor JJ, Hajdu SI, Magill GB, Tan C, Friedrich C, Brennan MF. A prospective randomised trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991; 68: 1221-9.
34. Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, et al. Phase III comparison of doxorubicin and dacabatzine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991; 83: 926-32.
35. Hasinoff BB. The interaction of the cardioprotective agent ICRF-187((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane: its hydrolysis product (ICRF-198) and other chelating agents with the Fe (III) and Cu (II) complexes of adriamycin. Agents Actions 1989; 26: 378-85.
36. Sparano JA, Speyer J, Gradishan W, et al. Phase I trial of zinecard, adriamycin, and escalating doses of taxol in advanced breast cancer (T95-0054). Breast Cancer Res Treat 1997; 46: 56 (abstr. 224).
37. Hochster H, Liebes L, Wadler S, et al. Pharmacokinetics of the cardioprotector ABR-529 (ICRF-187) in escalating doses combined with fixed-doses doxorubicin. J Natl Cancer Inst 1992; 84: 1725-30.
38. Jones V, Finucane D, Rodriguez R. Phase II study of weekly paclitaxel and liposomal doxorubicin in patients with locally advanced and metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19: 451.
39. Marty M. Liposomal doxorubicin (Myocet®) and conventional anthtacyclines: a comparison. Breast 2001; 10: 28-33.
40. Perez EA. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. Cancer Invest 2001; 19: 155-64.
41. Ciotti R, Ucci G, Belotti G, Facchi E, Cremonesi M, Gatti C, Baccheta G. Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it? J Clin Oncol 2001; 19: 4269-70.
42. Sundby Hall K, Wiklund T, Erikstein B, Holte H, Kvalheim G, Heen Sommer H, et al. Effects of dose-intensive chemotherapy and radiotherapy on setum N-terminal proatrial natriutetic pepride in high-risk breast cancer patients. Breast Cancer Res Treat 2001; 67: 235-44.
43. Sparano J. Use of dexzazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin Oncol 1998; 25: 66-71.
44. Sparano JA, Winer EP. Liposomal anthracyclines for breast cancer. Semin Oncol 2001; 28: 32-40.
45. Trudeau M, Pagani O. Epirubicin in combination with the taxanes. Semin Oncol 2001 ; 28: 41-50.